National Institute of Respiratory Diseases, Mexico

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Phase 4

Recruiting

Conditions: COPD Bronchitis
Pollution Related Respiratory Disorder

Interventions: Drug: Vilanterol / Umeclidinium (25/62.5 mcg)
Drug: Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)
Drug: Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg
Drug: Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 128

Registration Number: NCT06571942

Locations: 🇲🇽
Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Ciudad de México, Tlalpan, Mexico

Nutritional Therapy Enriched With Omega-3 in Patients With Lung Resection

Not Applicable

Recruiting

Conditions: Lung Cancer
Surgery

Interventions: Dietary Supplement: Fish oil oral supplementation
Dietary Supplement: Enteral nutrition without fish oil
Dietary Supplement: Oral nutritional supplement without fish oil
Dietary Supplement: Fish oil enteral supplementation

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 310

Registration Number: NCT06531460

Locations: 🇲🇽
National Institute of Respiratory Diseases, Mexico City, Mexico

Nutritional Therapy in Patients With Post-extubation Dysphagia

Not Applicable

Recruiting

Conditions: Dysphagia

Interventions: Other: High protein dose
Other: Usual protein dose

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 128

Registration Number: NCT06511284

Locations: 🇲🇽
National Institute of Respiratory Diseases, Mexico City, Mexico

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Phase 4

Recruiting

Conditions: Nicotine Addiction
Nicotine Replacement Therapy
Tobacco Smoking
Tobacco Withdrawal
Nicotine Withdrawal

Interventions: Drug: Nicotine replacement therapy (Nicotine patches)
Drug: Bupropion

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-23

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 134

Registration Number: NCT06254001

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, Ciudad de mexico, Mexico

Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City

Not Applicable

Not yet recruiting

Conditions: Histoplasmosis AIDS
Acquired Immunodeficiency Syndrome
Tuberculosis Infection
Cryptococcal Meningitis

Interventions: Diagnostic Test: Histoplasma Urine Antigen Lateral Flow Antigen test
Diagnostic Test: Cryptococcal Lateral Flow Antigen test
Diagnostic Test: Tuberculosis-lipoarabinomannan Lateral Flow Antigen test

First Posted Date: 2023-01-17

Last Posted Date: 2023-01-17

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 211

Registration Number: NCT05685641

Locations: 🇲🇽
General Hospital Dr. Manuel Gea Gonzalez, Mexico City, Mexico
🇲🇽
National Institute of Respiratory Diseases, Mexico City, Mexico
🇲🇽
National Institute of Cancerology, Mexico City, Mexico

and more 1 locations

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Indacaterol
Drug: Tiotropium

First Posted Date: 2022-08-18

Last Posted Date: 2022-08-18

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 97

Registration Number: NCT05506865

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

Phase 4

Completed

Conditions: COPD

Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcgs
Drug: Umeclidinium/Vilanterol 62.5/25 mcgs

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 133

Registration Number: NCT05342558

Locations: 🇲🇽
National Institute of Respiratory Diseases 'Ismael Cosío Villegas', Mexico City, Tlalpan, Mexico

Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.

Phase 2

Recruiting

Conditions: Interstitial Lung Disease
Rheumatoid Arthritis

Interventions: Drug: Tofacitinib

First Posted Date: 2022-02-18

Last Posted Date: 2023-04-27

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 60

Registration Number: NCT05246293

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Tlalpan, Mexico

Risk of Pneumothorax With and Without Chest Tube Clamping in Patients With Pleural Pathology

Not Applicable

Completed

Conditions: Pneumothorax
Chest Tube
Pleural Diseases

Interventions: Procedure: Non Clampling
Procedure: Clamping

First Posted Date: 2022-02-17

Last Posted Date: 2023-05-31

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 93

Registration Number: NCT05243316

Locations: 🇲🇽
National Institute of Respiratory Diseases, Mexico City, Mexico

Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study

Completed

Conditions: Covid19

First Posted Date: 2021-05-20

Last Posted Date: 2022-01-19

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 567

Registration Number: NCT04894760

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy